Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is mδarket-oriented and realizes industrial development through R&D inno≈vation and technology transformation.

key word:

Pharmaceutical innovative

Category:

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a large health industry finance↓ platform company integrating pharmaceutical, intelligent medical, bio p∞harmaceutical R&D, industrial production and sales.

The chemical reactions involved in the existing products i™nclude Foucault reaction, nitration reaction, sulfonation reaction, h ydrogenation reaction, fluorination reaction, chlorination reaction, bromination reaction, diaz otization reaction, format reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (DPP4)¶ inhibitor developed by Merck. In October 2006, Sitagliptin phosphate Januvia was apprδoved by FDA as the first DPP4 inhibitor for the treatment of type ⅱ diabetes mellitus. The cha&racteristics of this drug are that it can stimulate insulin secrαetion while reducing hunger without causing weight gain. Hypoglycemia and edema will not o©ccur, and it is suitable for diabetic patients with poor blood glu♠cose control and frequent hypoglycemia.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech ph>armaceutical enterprise that is market-oriented and realizes ind★ustrial development through R&D innovation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofen is one of the most importσant products for the treatment of arthritis. It is well tolerated and has a low incidence of s®ide effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotriene receptor≈ antagonists. In clinical application, it has good therapeutic efδfect on atopic asthma and other types of bronchial asthma, and the market prospect is huge. I"n the major category of asthma drugs, leukotriene receptor antagonists have≠ the fastest growing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that is market-orie☆nted and realizes industrial development through R&D innovatio•n and technology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is the‍ second drug approved by FDA for Alzheimer's diseas e in the United States. Its treatment reaches the target dose and has low toxic and side¥ effects. It has been widely recognized by our medical community, and good tolerance is it¶s biggest advantage. In October 1999, Donepezil was launched in China under the t rade name "Aricept", which is the main chemical drug against ₽Alzheimer's disease. At present, CFDA has approved a number of domestic enterpr★ises to produce donepezil preparations, the main dosage forms are tablets, capsules, dispersεive tablets, oral disintegrating tablets.

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol-Myers Squibb∑/Pfizer), a direct oral factor Xa inhibitor, was appr'oved for use in the 27 EU member states. The world's first drug appro™ved to prevent venous thromboembolism (VTE) in adu lt patients undergoing elective hip or knee replacemen₹t. From June 2019 to June 2020, the annual sales of apixaban products overseas reac∏hed about $15.4 billion, with a year-on-year growth of nearly 32%, and the API consumption r eached about 23,960 kg, with a year-on-year growth of about 28%. Compared with →its main competitor, Rivaroxaban, the drug's annual o®verseas sales are about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that i§s market-oriented and realizes industrial development t↔hrough R&D innovation and technology transformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by Genzyme. On December ♣29, 2004, it was approved by FDA for the treatment o•f refractory or relapsed acute lymphoblastic leukemia (ALL) i$n children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise ↓that is market-oriented and realizes industrial development ♣through R&D innovation and technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). If you n→eed other services, E-mail: 2880705932@qq.com
Submit

Copyright © 2022 Anhui Union Pharmaceuticals Technolo'gy Co., Ltd.